Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor ... while driving significant reductions in plasma levels of very long-chain fatty ...

The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor ... while driving significant reductions in plasma levels of very long-chain fatty ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of ...

The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor ... while driving significant reductions in plasma levels of very long-chain fatty ...

The company plans to file an investigational new drug application with the FDA later this year to advance an internally ...

For the first time, scientists have 'photographed' a rare plasma instability, where high-energy electron beams form into spaghetti-like filaments. A new study, published in Physical Review Letters ...

The Plasma Burst Laser is a hitscan weapon that operates on durability rather than ammo (plus it packs quite an explosive punch). However, the Plasma Burst Laser isn’t the easiest item to come by.

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...